Shire has acquired the rights to develop and market Resolor (prucalopride) in the United States in an agreement with Janssen Pharmaceutica.
Resolor, a prokinetic, is part of Shire’s gastrointestinal portfolio in Europe and is approved for use in 33 countries for the symptomatic treatment of chronic constipation in women. Resolor is available in Germany, Ireland, Belgium, France, Greece, and the United Kingdom, and will be commercially available in Italy in mid-January 2012. Additional launches throughout Europe are planned for 2012.
Resolor was developed for the European market by the Belgian-based pharmaceutical company Movetis, which acquired the European rights to Resolor from Janssen Pharmaceutica. Shire acquired Movetis in 2010.
Under the terms of the agreement, the U.S. rights to the Resolor trademark will be transferred to Shire.
Release Date: Jan. 10, 2012